Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV

Prolonged evolution of the human B cell response to SARS-CoV-2 infection

(2021) Mrunal Sakharkar et al.   Science Immunology

COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State

(2021) James M. Tesoriero et al.   JAMA Network Open

Durable SARS-CoV-2 B cell immunity after mild or severe disease

(2021) Clinton O. Ogega et al.   JOURNAL OF CLINICAL INVESTIGATION

Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19

(2021) Nicole Doria-Rose et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in persons with HIV

(2021) Jake A. Ruddy et al.   AIDS

Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1

(2021) Itzchak Levy et al.   CLINICAL MICROBIOLOGY AND INFECTION

Immunological Changes after COVID-19 Vaccination in an HIV-Positive Patient

(2021) Changlin Gong et al.   INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES

Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey

(2021) Mine Durusu Tanriover et al.   LANCET

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

(2021) Moriah Bergwerk et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

(2021) John Frater et al.   Lancet HIV

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial

(2021) Shabir A Madhi et al.   Lancet HIV

Differences in Post-mRNA Vaccination SARS-CoV-2 IgG Concentrations and Surrogate Virus Neutralization Test Response by HIV Status and Type of Vaccine: a Matched Case-Control Observational Study

(2021) Matthew A Spinelli et al.   CLINICAL INFECTIOUS DISEASES

Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months

(2021) Einav G. Levin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Antibody Persistence 6 Months Post-Vaccination with BNT162b2 among Health Care Workers

(2021) Flaminia Campo et al.   Vaccines

Coronavirus disease 2019 (COVID‐19) outcomes in HIV/AIDS patients: a systematic review

(2020) TJ Cooper et al.   HIV MEDICINE

Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study

(2020) Anna Maria Geretti et al.   CLINICAL INFECTIOUS DISEASES

Risk factors for COVID-19 death in a population cohort study from the Western Cape Province, South Africa

(2020) Andrew Boulle et al.   CLINICAL INFECTIOUS DISEASES

COVID‐19 in people living with HIV: Clinical implications of dynamics of the immune response to SARS‐CoV‐2

(2020) Annalisa Mondi et al.   JOURNAL OF MEDICAL VIROLOGY

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial

(2020) Shengli Xia et al.   LANCET INFECTIOUS DISEASES

Routine CD4 monitoring in HIV patients with viral suppression: Is it really necessary? A Portuguese cohort

(2017) Raquel Duro et al.   JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients

(2016) Vivian I. Avelino-Silva et al.   PLoS Neglected Tropical Diseases

HIV infection

(2015) Steven G. Deeks et al.   Nature Reviews Disease Primers